Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral Healthlucet TMS Coverage Update Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedlucetPolicy 20.5.008

    Transcranial Magnetic Stimulation (TMS) for Major Depression

    Customize your policy alerts

    Sign up for lucet Policy 20.5.008 alerts

    Get alerted when Policy 20.5.008 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing coverage and medical necessity criteria for transcranial magnetic stimulation (TMS) to treat major depressive disorder, including training requirements, eligible patient criteria, treatment protocols, exclusions, and coding guidance for providers and clinics seeking authorization.

    Policy Summary
    Payerlucet
    PolicyTranscranial Magnetic Stimulation (TMS) for Major Depression
    Policy CodePolicy 20.5.008
    Change TypeClarified ECT guidanceadded pediatric indicationupdated evidence
    Effective DateFeb 1, 2025
    Last ReviewSep 1, 2025
    Next Review Date
    Key ActionSubmit a completed TMS Request Form with required documentation including clinician certification, baseline depression rating scale score, and CPT units (90867, 36×90868, 90869) for initial authorization.
    SourceLink
    POLICY UPDATE CHANGES

    Clarified language regarding ECT recommendations.

    Add child and adolescent indication from the FDA.

    Updated the summary of evidence.

    Florida Blue requires age to start at 15 years old.

    10 references removed.

    3 references added.

    6 weeks + taperacute course
    15-70eligible age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2 trials
    pharmacologic failures
    90867/90868/90869example CPT units
    1request form
    09/2025most recent rev

    Coverage and Medical Necessity Criteria

    Initial Authorization Criteria

    Initial Authorization — TMS meets medical necessity for treatment-resistant major depressive disorder when ALL of the following are met:

    Initial Authorization Criteria: a. Confirmed diagnosis of severe Major Depressive Disorder WITHOUT psychosis (ICD-9 296.2x/296.3X; ICD-10 F32.x/F33.x) with severity documented by one clinically accepted depression rating scale from Table 1; b. Member age between 15 and 70; c. Any ONE of the following: (i) Failure of two trials of FDA‑approved antidepressant medications, including trials from at least two different antidepressant classes; OR (ii) Inability to tolerate therapeutic doses documented by two trials from at least two different antidepressant classes with distinct intolerable side effects; OR (iii) Meets ECT policy criteria and has been evaluated for ECT but clinical circumstances prevent ECT and ECT outcome would not be overall superior to TMS (note: TMS should not be utilized when psychosis, acute suicidal risk, catatonia, or life‑threatening dysfunction are present).

    Retreatment Criteria

    Retreatment Authorization — Retreatment (repeat acute treatment) is medically necessary when BOTH:

    Retreatment Criteria: a. Member meets all initial TMS treatment requirements; b. Documentation that the member previously responded to TMS with ≥50% improvement on a standard depressive symptom rating scale (Table 1) AND at least 90 days have elapsed since completion of the prior TMS course.>=50% improvement; >=90 days since prior course

    Delivery and Monitoring Requirements

    Treatment delivery and monitoring requirements

    Delivery and Monitoring: TMS must be delivered using an FDA‑approved or cleared device; a board‑certified psychiatrist trained in TMS must personally perform the first treatment including cortical mapping and motor threshold determination (and re‑determination as needed); subsequent treatments may be administered by a psychiatrist or a certified TMS technician; a single standardized depression rating scale (Table 1) should be selected and administered prior to the initial treatment, every two weeks during the six‑week initial course, and at the final visit for monitoring; if rating scales show lack of meaningful change or worsening, physician review is indicated; typical acute schedule is one session per day, 5 days/week for 6 consecutive weeks followed by a 3‑week taper (week 1: 3 sessions; week 2: 2 sessions; week 3: 1 session).6‑week course with specified 3‑week taper

    Psychiatrist must perform first session and motor threshold determination; technician must be certified if administering subsequent sessions.

    The policy identifies several clinical and technical situations in which TMS is considered inappropriate or may be denied. TMS is not appropriate for patients with active psychotic symptoms, acute suicidal risk, or catatonia. Requests are also inappropriate when the member has life‑threatening dysfunction in basic life needs or an active neurologic disorder (examples listed include encephalopathy, dementia, Parkinson’s disease, post‑stroke syndromes, increased intracranial pressure or bleeding, cerebral aneurysm, arteriovenous malformations, CSF shunts, or implants in the CNS or head/neck).

    Policy history notes a September 2025 revision by the Medical Policy Workgroup that clarified language regarding ECT recommendations and added pediatric/child and adolescent indication language from the FDA. Local payer requirements may vary; the document records that Florida Blue requires a minimum treatment start age of 15 years, which may affect application of ECT‑related considerations or authorization procedures.

    The policy explicitly identifies several request types that are not supported under the coverage criteria: Maintenance TMS, Intermittent Theta Burst Stimulation (iTBS), Magnetic Seizure Therapy (MST), and Navigated TMS (nTMS). It also states that requests for TMS to treat psychiatric diagnoses other than treatment‑resistant major depressive disorder — for example OCD — are not appropriate.

    Within the available document excerpts there are no standalone, additional statements framed as a universal "not medically necessary" list beyond the exclusions and modality limitations already recorded. Instead, the policy history indicates substantive edits in 09/2025 (including clarifications about ECT and pediatric indications) that may change local application; implementers should refer to the full policy and any payer‑specific guidance for explicit denial language.

    Diagnosis, Procedure Codes, and Rating Scales

    Referenced diagnosis codesICD-10
    F32.xMajor depressive disorder
    F33.xMajor depressive disorder
    Referenced historical diagnosis codesmixed
    ICD-9 296.2xMajor depressive disorder
    ICD-9 296.3XMajor depressive disorder
    Referenced procedure/CPT codesCPT
    90867CPT example unit listed for initial authorization (interpretation/testing)
    90868CPT example units listed (repetitive TMS delivery) — 36 units for initial and retreatment
    90869CPT example unit listed for initial authorization (stimulation parameter adjustment) — one unit initial; additional units require rationale
    Clinically accepted depression rating scales and threshold scores (Table 1)mixed
    BDIBeck Depression Inventory — minimum score for initial authorization: >29
    IDS-CInventory of Depressive Symptomatology Clinician-rated — minimum score for initial authorization: >36
    QIDS-SRQuick Inventory of Depressive Symptomatology Self-reported — minimum score for initial authorization: >15
    MADRSMontgomery-Asberg Depression Rating Scale — minimum score for initial authorization: >34
    PHQ-9Patient Health Questionnaire (PHQ-9) — minimum score for initial authorization: >19
    Depression rating scale thresholds — Table 1
    Beck Depression Inventory (BDI)21 items; minimum score for initial authorization: >29
    Inventory of Depressive Symptomatology — Clinician-rated (IDS-C)30 items; minimum score for initial authorization: >36
    Quick Inventory of Depressive Symptomatology — Self-report (QIDS-SR)16 items; minimum score for initial authorization: >15
    Montgomery‑Åsberg Depression Rating Scale (MADRS)10 items; minimum score for initial authorization: >34
    Patient Health Questionnaire (PHQ‑9)9 items; minimum score for initial authorization: >19

    Provider Requirements, Prior Authorization, and Forms

    Billing Rule

    Prior authorization coding and unit requirements

    Initial authorization requests must include CPT coding and unit counts exactly as specified: submit one (1) unit of CPT 90867, thirty-six (36) units of CPT 90868, and one (1) unit of CPT 90869 for the initial course. Requests for additional units of 90869 must be submitted with detailed clinical rationale; retreatment requests should request thirty-six (36) units of 90868.

    • Initial course: 1 × 90867; 36 × 90868; 1 × 90869.
    • Additional 90869 units require a detailed clinical rationale.
    • Retreatment: 36 × 90868.
    Prior Authorization

    Prior authorization form and payer age note

    Permitted and Unsupported TMS Modalities

    rTMS

    rTMS (repetitive TMS): Delivered with an FDA‑cleared device per policy schedule; appropriate for treatment‑resistant major depressive disorder meeting initial authorization criteria; first session performed by a trained psychiatrist with motor threshold mapping; standardized rating scales used for baseline and ongoing monitoring.

    iTBS / MST / nTMS / Accelerated TBS / Maintenance TMS

    Modalities considered investigational or not appropriate: Intermittent theta‑burst stimulation (iTBS), Magnetic Seizure Therapy (MST), Navigated TMS (nTMS), Accelerated TBS/SNT protocols, and Maintenance TMS are noted as investigational, not appropriate, or lacking agreed‑upon protocols in the evidence base and are considered not medically necessary for routine coverage in this policy excerpt.

    Evidence summaries cite small or limited trials for some accelerated/targeted protocols and note need for further trials and durability data.

    TMS / rTMS / deep TMS

    Outpatient and Site-of-Care Criteria

    Outpatient TMS Level‑of‑Care Criteria

    Outpatient TMS level of care: Admission to outpatient TMS requires confirmed severe MDD without psychosis, age 15–70, documentation of required prior medication trials or documented intolerance or ECT consideration per initial authorization criteria, and a baseline depression rating scale score from Table 1; continued treatment during the acute course requires ongoing monitoring with the same standardized scale at least every two weeks and physician review if no meaningful improvement.

    One session per day, 5 days/week for 6 weeks with 3‑week taper as specified in delivery requirements.

    Treatment Frequency and Visit Limits

    TMS treatment sessions (acute course)
    Typical session frequencyOne (1) treatment session per day, five (5) consecutive days per week during the acute course
    Acute course durationSix (6) consecutive weeks for the initial treatment period
    Post-course taper scheduleWeek 1: 3 sessions; Week 2: 2 sessions; Week 3: 1 session

    Definitions

    Transcranial Magnetic Stimulation (TMS)
    DefinitionTranscranial magnetic stimulation (TMS) is a noninvasive treatment that uses a magnetic field to influence brain activity delivered with an FDA-approved or cleared device.
    First-treatment requirementPsychiatrist must perform the first TMS treatment including cortical mapping and motor threshold determination.
    Common side effectsSide effects are usually mild and temporary (as noted in the policy).
    Treatment-resistant depression (TRD) — policy definition
    Policy definition of TRDMajor Depressive Disorder without psychosis after failure of two adequate trials of FDA‑approved antidepressants from at least two different classes, or documented intolerance to such medications, with severity documented by an accepted rating scale.
    Alternative pathway — ECT consideration

    Background and Rationale

    Transcranial magnetic stimulation (TMS) is a noninvasive neuromodulation technique that uses time‑varying magnetic fields to influence brain activity and is used primarily to treat major depressive disorder after other treatments have failed. The policy references TMS modalities including repetitive TMS (rTMS) and deep TMS, and cites clinical evidence and guideline literature supporting rTMS for treatment‑resistant depression while noting that alternative or novel protocols (for example, accelerated or navigated approaches) have limited or investigational evidence.

    Document History and Revisions

    2025-09-01revisionLatest

    Clarified language regarding ECT recommendations and added child and adolescent indication per FDA; updated summary of evidence and revised references list (10 removed, 3 added).

    2025-09-01clarification

    Medical Policy Workgroup clarified ECT recommendation language and added pediatric (child and adolescent) indication on 09/2025.

    2025-02-01
    Policy Summary
    Payerlucet
    PolicyTranscranial Magnetic Stimulation (TMS) for Major Depression
    Policy CodePolicy 20.5.008
    Change TypeClarified ECT guidanceadded pediatric indicationupdated evidence
    Effective DateFeb 1, 2025
    Last ReviewSep 1, 2025
    Next Review Date
    Key ActionSubmit a completed TMS Request Form with required documentation including clinician certification, baseline depression rating scale score, and CPT units (90867, 36×90868, 90869) for initial authorization.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaDiagnosis, Procedure Codes, and Rating ScalesProvider Requirements, Prior Authorization, and FormsPermitted and Unsupported TMS ModalitiesOutpatient and Site-of-Care CriteriaTreatment Frequency and Visit LimitsDefinitionsBackground and RationaleDocument History and Revisions

    Use the Transcranial Magnetic Stimulation (TMS) Request Form provided in the policy when submitting authorization requests. Note the policy history: an external payer (Florida Blue) requires initiation age to start at 15 years, which may affect prior authorization decisions for some members.

    • TMS Request Form link available in policy FORMS section.
    • Florida Blue-specific start age noted in document history (age 15).
    Step Therapy

    Step‑therapy: required prior antidepressant trials

    Prior to authorization, document failure of two (2) adequate trials of FDA‑approved antidepressant medications from at least two (2) different antidepressant classes, or documented intolerance to such medications (two trials from at least two different classes with distinct intolerable side effects).

    • Failure of two adequate trials including trials from at least two different antidepressant classes (e.g., SSRI, SNRI, TCA, MAOI).
    • Or documented inability to tolerate therapeutic doses shown by two trials from at least two different classes with distinct intolerable side effects.
    Note

    Other provider submission requirements (placeholder)

    No additional label provided in inventory — ensure other listed provider actions are submitted with the authorization request per policy (coding/units, forms, treatment history, documentation of technician/psychiatrist roles, and rating scale scores).

    • Include required coding/units and TMS Request Form when applicable.
    • Attach prior medication trial documentation and rating scale scores.
    • Confirm clinician roles (psychiatrist performed first treatment/motor threshold).
    Documentation Required

    Required documentation to support authorization

    Attach documentation of clinic/practitioner registration/certification, evidence that a board‑certified psychiatrist performed the first TMS treatment and motor threshold determination, documentation of psychiatrist oversight, and technician certification if technicians administer subsequent sessions. Also include a baseline score from one clinically accepted depression rating scale (Table 1) prior to the initial 6‑week treatment course.

    • Clinic/practitioner registration/certification prior to benefit use.
    • Board‑certified psychiatrist performed first treatment, cortical mapping, and motor threshold determination.
    • Evidence of psychiatrist oversight for the course; technician certification when technicians administer sessions.
    • Baseline depression rating scale score from Table 1 (BDI, IDS‑C, QIDS‑SR, MADRS, or PHQ‑9).
    Prior Authorization

    Use the TMS Request Form when requesting authorization

    Providers may use the Transcranial Magnetic Stimulation (TMS) Request Form linked in the policy FORMS section when requesting authorization for TMS services.

    • Form link provided in FORMS section of the policy.
    Denial Risk

    Conditions that increase risk of denial or noncoverage

    Requests may be considered not appropriate or medically necessary — and thus at risk for denial — for members with active substance abuse, active psychotic symptoms, acute suicidal risk, catatonia, life‑threatening dysfunction in basic life needs, active neurologic disorders (e.g., encephalopathy, dementia, Parkinson’s, post‑stroke syndromes, increased intracranial pressure/bleeding, cerebral aneurysm, AV malformations, CSF shunts, CNS/head/neck implants), psychiatric diagnoses other than treatment‑resistant depression, OCD, maintenance TMS, iTBS, MST, and navigated TMS.

    • Active substance abuse (UDS confirmation may be required).
    • Active psychotic symptoms or acute suicidal risk.
    • Catatonia or life‑threatening dysfunction in basic life needs.
    • Active neurologic disorders or non‑removable metallic implants in head/neck.
    • Requests for diagnoses other than treatment‑resistant depression, OCD, maintenance TMS, iTBS, MST, or nTMS.
    Denial Risk

    No other explicit denial triggers in this section; check document history

    The policy text does not present additional, separate explicit denial triggers beyond the conditions listed in exclusions and not‑medically‑necessary sections; document history notes clarifications (e.g., ECT guidance) and an external payer age requirement. Verify exclusions and updated policy history when submitting requests.

    • No other explicit denial triggers are listed in these document sections.
    • Document history (09/2025) includes clarifications regarding ECT and notes Florida Blue age requirement of 15 years.
    TMS modality distinctions: Deep TMS and other device‑specific approaches are addressed in the evidence citations; while deep TMS has been evaluated in some disorders (e.g., OCD) and post‑marketing analyses exist, clinical criteria in this policy apply to FDA‑cleared devices for treatment‑resistant major depressive disorder and do not expand coverage to device‑specific indications outside the stated criteria.

    References summarize variable quality evidence for deep TMS and other modalities; policy limits coverage to modalities consistent with the criteria.

    If member meets ECT policy and has been evaluated for ECT but ECT is prevented by clinical circumstances and ECT outcome would not be overall superior to TMS, TMS may be considered.
    Age requirementMember must be between 15 and 70 years of age for initial authorization.
    Treatment-resistant depression — additional references
    Literature on TRD definition and managementWorld Psychiatry (2023) review defines treatment‑resistant depression: detection, prevalence, management, and investigational interventions.
    VA/DoD guideline synopsis (2022)Management recommendations and context for defining adequate trials and treatment planning are summarized in VA/DoD guidance.
    Adolescent TMS evidenceSystematic reviews and meta‑analyses address rTMS in children and adolescents and provide contextual evidence referenced by the policy.
    creation

    Policy created (effective 02/2025) by Dr. J. Langlow; noted payer-specific age requirement that Florida Blue requires starting age of 15 years old.